Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat
Ben P Martin, Ailsa J Frew, Michael Bots, Stephen Fox, Fenella Long, Kazuyoshi Takeda, Hideo Yagita, Peter Atadja, Mark J Smyth, Ricky W Johnstone
International Journal of Cancer | WILEY-BLACKWELL | Published : 2011
R.W.J. is the recipient of a collaborative research grant from Novartis for work involving panobinostat. P.A. is a paid employee of Novartis.R.W.J. is a Principal Research Fellow of the National Health and Medical Research Council of Australia (NHMRC) and supported by NHMRC Program and Project Grants, the Susan G. Komen Breast Cancer Foundation, the Prostate Cancer Foundation of Australia, Cancer Council Victoria, Victorian Breast Cancer Research Consortium and a research grant from Novartis. A.J.F. is supported by The Cancer Council Victoria. M.J.S. is a Senior Principal Research Fellow of the NHMRC and is supported by the Susan G. Komen Breast Cancer Foundation and NHMRC Program and Project Grants. M. B. is supported by a Rubicon research grant from Netherlands Organisation for Scientific Research (NWO). K.T. and H.Y. are supported by the Ministry of Education, Science and Culture, Japan.